Skip to main content

Cyteir Therapeutics, Inc.

CYTDelisted Mar 18, 2024
Industry
Pharmaceutical Preparations
SEC CIK
0001662244

Cyteir Therapeutics, Inc. was delisted on Mar 18, 2024; its insiders filed their last Form 4 on Mar 25, 2024; 38 institutions reported holding it in 13F filings for Q4 2023, worth $38.9M in total; no superinvestor held it.

Key figures

Insider buys
0
Open market, last 90 days
Insider sells
0
Open market, last 90 days
13F holders
38
Q4 2023, −2 vs. previous quarter
13F value
$38.9M
Reported value at the end of Q4 2023
Superinvestors holding
0
At the end of Q4 2023

Superinvestors holding CYT, Q4 2023

Go to the superinvestors tab

No superinvestor reported holding CYT at the end of Q4 2023.

Latest insider trades

Open-market purchases and sales by Cyteir Therapeutics, Inc. insiders from Form 4, newest first.

See all insider trades
Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Mar 25, 2024 (view filing)Mar 205 daysLateLeonard Braden Michael10% OwnerPPurchaseCommon Stock, par value $0.001 per share+170.6K$2.95+$503.2K+4.9%3.65M after
Mar 19, 2024 (view filing)Mar 181 dayLeonard Braden Michael10% OwnerPPurchaseCommon Stock, par value $0.001 per share+113.8K$3.01+$342.5K+3.4%3.48M after
Jul 20, 2023 (view filing)Jul 19-201 dayNovo Holdings A/S10% OwnerSSale−101.9K$2.75−$280.2K−2.8%3.52M after2 lots
Jul 18, 2023 (view filing)Jul 14-184 daysNovo Holdings A/S10% OwnerSSale−38.6K$2.75−$106.1K−1.1%3.62M after3 lots
Jul 3, 2023 (view filing)Jun 303 daysNovo Holdings A/S10% OwnerSSale−200.9K$2.63−$528.5K−5.2%3.66M after
Jun 28, 2023 (view filing)Jun 26-272 daysNovo Holdings A/S10% OwnerSSale−40.4K$1.77−$71.7K−1.0%3.86M after2 lots
Jun 23, 2023 (view filing)Jun 21-232 daysNovo Holdings A/S10% OwnerSSale−13.3K$1.94−$25.8K−0.3%3.90M after3 lots
Jun 20, 2023 (view filing)Jun 15-205 daysNovo Holdings A/S10% OwnerSSale−16.7K$2.03−$34.0K−0.4%3.92M after3 lots
Jun 14, 2023 (view filing)Jun 12-142 daysNovo Holdings A/S10% OwnerSSale−6.40K$2.10−$13.4K−0.2%3.93M after3 lots
Dec 8, 2022 (view filing)Dec 71 dayZakrzewski Joseph SDirectorPPurchase+21.2K$1.30+$27.6K+15.9%154.6K afterFrom original

Top 10 13F holders, Q4 2023

The largest institutional positions in Cyteir Therapeutics, Inc. at the end of Q4 2023; share changes are against Q3 2023.

See all 38 holders
Institutions holding CYT in Q4 2023
InstitutionSharesValue% of portfolioChange in sharesAction
BML Capital Management, LLC3,250,008$9.88M7.80%00.0%Unchanged
Newtyn Management, LLC3,021,500$9.19M1.80%+521,056+20.8%Added
Gabelli Funds LLC1,110,050$3.37M0.03%+667,412+150.8%Added
Anson Funds Management LP1,096,422$3.33M0.69%−227,692−17.2%Reduced
Gabelli & Co Investment Advisers, Inc.1,026,000$3.12M0.59%+609,800+146.5%Added
Vanguard Group Inc687,391$2.09M0.00%+46,611+7.3%Added
Millennium Management LLC451,980$1.37M0.00%+451,980New
Walleye Capital LLC427,037$1.30M0.02%+73,121+20.7%Added
Laurion Capital Management LP316,201$961.3K0.03%−43,299−12.0%Reduced
Bulldog Investors, LLP200,000$608.0K0.20%00.0%Unchanged